Our Commitment To Breast Cancer Patients
At Context Therapeutics, we are passionate about improving health and committed to helping people with cancer.
Through our Onward Breast Cancer Clinical Trials, we will evaluate Apristor® as a monotherapy (ONWARD 201) and in combination (ONWARD 202) with standard of care drugs across multiple metastatic breast cancer treatment lines. Onward 201 will evaluate Apristor in second line (2L) metastatic breast cancer patients who are PR+ and have failed prior endocrine therapy, including Cdk4/6-resistant and ESR1 mutant patients. Onward 202 will evaluate Apristor in first line (1L) metastatic breast cancer patients who are PR+ and in combination with one of three standard of care agents (letrozole, fulvestrant, or palbociclib).
Developing the next generation of antihormonal therapies to treat breast, prostate, and ovarian cancers.
Apristor is an investigational New Chemical Entity (NCE) for PR+ breast and ovarian cancers.